Brief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
01/09/2026 22:03
BRIEF-Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award Sept 1 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO:
CIPHER PHARMACEUTICALS RECEIVES FAVOURABLE DECISION CONFIRMING ARBITRATION AWARD
CIPHER PHARMACEUTICALS - COURT DENIES SUN PETITION AND CONFIRMS ARBITRATION AWARD IN FAVOUR OF CIPHER
CIPHER PHARMACEUTICALS - AWARDED 15% ROYALTY ON ABSORICA LD SALES IN CANADA FROM 2026 TO 2040
CIPHER PHARMACEUTICALS - COURT AWARDS CIPHER INTEREST ON DAMAGES AND LEGAL FEES AT 9% PER ANNUM
CIPHER PHARMACEUTICALS - INTENDS TO PURSUE CLAIMS AGAINST SUN IN OTHER JURISDICTIONS
CIPHER PHARMACEUTICALS - COURT AWARDS CIPHER ADDITIONAL INTEREST UNTIL JUDGMENT IS SATISFIED
Source text: ID:nCNW758Xfa
Further company coverage: CPH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million